• In the second quarter of 2026, Alnylam Pharmaceuticals reported revenue of US$1,290.95 million and net income of US$164.49 million, a shift from a net loss a year earlier, and for the first half of 2026 revenue reached US$2,458.12 million with net income of US$370.49 million.
• On the same day, the company trimmed its full-year 2026 guidance for total net product revenues while raising expectations for collaboration and royalty income, highlighting a changing balance between its own drug sales and partnered revenue streams.
• We’ll now examine how the lowered TTR franchise revenue outlook, despite strong overall earnings, affects Alnylam’s longer-term investment narrative.

Rare earth metals are the new gold rush. Find out which 28 stocks are leading the charge.

Alnylam Pharmaceuticals Investment Narrative Recap

To own Alnylam, you need to believe its RNAi platform and TTR franchise can support durable profitability while the broader pipeline gradually reduces dependence on AMVUTTRA. The recent TTR guidance cut directly touches the key near term catalyst and main risk: how resilient TTR revenues are as initial cardiomyopathy demand normalizes. Despite strong Q2 earnings, the guidance move makes that concentration risk more visible rather than resolving it.

The most relevant announcement here is the July 30 guidance update, which lowered 2026 net product revenue expectations to US$4,700 million to US$5,100 million while lifting collaboration and royalty guidance to US$575 million to US$625 million. That shift underlines a subtle but important tilt in the story: near term focus is now less about pure AMVUTTRA upside and more about how partnered programs and royalties can help offset franchise volatility and support future catalysts.

Yet beneath the strong recent profits, investors should be aware that concentrated exposure to TTR therapies means...

Alnylam Pharmaceuticals' narrative projects $9.0 billion revenue and $2.0 billion earnings by 2029.

Uncover how Alnylam Pharmaceuticals' forecasts yield a $434.72 fair value, a 97% upside to its current price.

Exploring Other Perspectives

Before this guidance cut, the most cautious analysts were already warning that early AMVUTTRA saturation could slow growth, even as they still modeled about US$8.5 billion of 2029 revenue and US$1.2 billion of earnings, reminding you that reasonable people can read the same numbers very differently and that this latest TTR reset may push some to rethink those expectations.

Explore 5 other fair value estimates on Alnylam Pharmaceuticals - why the stock might be worth just $305.63!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Alnylam Pharmaceuticals research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free Alnylam Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Alnylam Pharmaceuticals' overall financial health at a glance.

Interested In Other Possibilities?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• Invest in the nuclear renaissance through our list of 90 elite nuclear energy infrastructure plays powering the global AI revolution.
• Uncover the next big thing with 19 elite penny stocks that balance risk and reward.
• Find 49 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.